During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

NEW YORK – In cell and gene therapies, the genetic machinery is key to producing the proteins missing or dysregulated in a disease, but whether the therapeutic cassette reaches target cells and how ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Etiome will use its Temporal Biodynamics platform to stage serious, progressive chronic diseases and develop targeted therapeutics.